Contraindications of incretin therapy: difference between revisions
Diff·revision 9 → 10·13:44, 8 Mar 2025
Difference between revision 9 and revision 10 of Contraindications of incretin therapy. 6 lines changed; the page grew by 162 bytes.
| Revision 9 — 19:45, 23 Feb 2025 Chromatokid (talk) move a stray full stop inside the reference 3,408 bytes +34 | Revision 10 — 13:44, 8 Mar 2025 INN_Ingrid (talk) expand §Scope of this article 3,570 bytes +162 | ||
|---|---|---|---|
| 36 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 36 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| 37 | 37 | ||
| + | 38 | == See also == | |
| + | 39 | * [[Adverse effects of GLP-1 receptor agonists]] | |
| + | 40 | * [[Hypoglycaemia]] | |
| + | 41 | * [[Aspiration risk under anaesthesia]] | |
| + | 42 | * [[Pregnancy and incretin therapy]] | |
| + | 43 | ||
| 38 | {{DEFAULTSORT:Contraindications of incretin therapy}} | 44 | {{DEFAULTSORT:Contraindications of incretin therapy}} |
| 39 | [[Category:Contraindications and cautions]] | 45 | [[Category:Contraindications and cautions]] |